Bacterial Vaginosis - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bacterial Vaginosis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Bacterial Vaginosis - Pipeline Review, H2 2015', provides an overview of the Bacterial Vaginosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bacterial Vaginosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bacterial Vaginosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacterial Vaginosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Vaginosis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Vaginosis - Overview 7
Pipeline Products for Bacterial Vaginosis - Comparative Analysis 8
Bacterial Vaginosis - Therapeutics under Development by Companies 9
Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes 10
Bacterial Vaginosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bacterial Vaginosis - Products under Development by Companies 14
Bacterial Vaginosis - Products under Investigation by Universities/Institutes 15
Bacterial Vaginosis - Companies Involved in Therapeutics Development 16
Alfa Wassermann S.p.A 16
AmVac AG 17
Osel Inc. 18
Starpharma Holdings Limited 19
Symbiomix Therapeutics, LLC 20
Bacterial Vaginosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AMV-100 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
astodrimer - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
benzoyl peroxide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LACTIN-V - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Peptide for Bacterial Vaginosis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rifaximin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
secnidazole - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Bacterial Vaginosis - Recent Pipeline Updates 38
Bacterial Vaginosis - Dormant Projects 45
Bacterial Vaginosis - Discontinued Products 46
Bacterial Vaginosis - Product Development Milestones 47
Featured News & Press Releases 47
Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis 47
May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 47
Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 48
Nov 21, 2014: SYM-1219 Chosen as one of the "Top Infectious Disease Projects" to Watch by Therapeutic Area Partnerships 49
Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis 49
Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 50
May 17, 2014: Phase 2 Clinical Trial Investigator Meeting Held in Dallas, Texas, May 17, 2014 51
Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis 51
Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis 53
Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Bacterial Vaginosis, H2 2015 7
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Bacterial Vaginosis - Pipeline by Alfa Wassermann S.p.A, H2 2015 16
Bacterial Vaginosis - Pipeline by AmVac AG, H2 2015 17
Bacterial Vaginosis - Pipeline by Osel Inc., H2 2015 18
Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H2 2015 19
Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics, LLC, H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Bacterial Vaginosis Therapeutics - Recent Pipeline Updates, H2 2015 38
Bacterial Vaginosis - Dormant Projects, H2 2015 45
Bacterial Vaginosis - Discontinued Products, H2 2015 46